Bevacizumab (Bev) with or without erlotinib as maintenance therapy, in patients (pts) with metastatic colorectal cancer (mCRC): Exploratory analysis according to KRAS status in the gercor DREAM phase III trial

被引：0
|
作者：
Samson, Benoit
Tournigand, Christophe
Scheithauer, Werner
Lledo, Gerard
Viret, Frederic
Andre, Thierry
Ramee, Jean Francois
Tubiana-Mathieu, Nicole
Dauba, Jerome
Dupuis, Olivier
Rinaldi, Yves
Mabro, May
Aucoin, Nathalie
Khalil, Ahmed
Latreille, Jean
Louvet, Christophe
Brusquant, David
Bonnetain, Franck
Chibaudel, Benoist
De Gramont, Aimery
机构：
[1] Hop Charles LeMoyne, Quebec City, PQ, Canada
[2] Hop Henri Mondor, F-94010 Creteil, France
[3] Med Univ Vienna, Vienna, Austria
[4] Hop Prive Jean Mermoz, Lyon, France
[5] Inst J Paoli I Calmettes, F-13009 Marseille, France
[6] Hop St Antoine, F-75571 Paris, France
[7] Ctr Catherine Sienne, Nantes, France
[8] CHU Limoges, Limoges, France
[9] Ctr Hosp Layne, Mt De Marsan, France
[10] Clin Victor Hugo, Le Mans, France
[11] Hop Ambroise Pare, Marseille, France
[12] Hop Foch, Suresnes, France
[13] Cite Sante Laval, Laval, PQ, Canada
[14] Hop Tenon, F-75970 Paris, France
[15] Hop Charles LeMoyne, Greenfield Pk, PQ, Canada
[16] Inst Mutualiste Montsouris, Dept Oncol, Paris, France
[17] GERCOR, Paris, France
[18] CHU Besancon, F-25030 Besancon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.448
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
448
引用
收藏
页数：1
相关论文
共 50 条
  • [21] SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6+selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC).
    Gibbs, Peter
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Gebski, Val
    Van Buskirk, Mark
    Van Hazel, Guy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Salvatore, L.
    Loupakis, F.
    Cremolini, C.
    Lupi, C.
    Masi, G.
    Sensi, E.
    Stasi, I
    Fornaro, L.
    Vasile, E.
    Schirripa, M.
    Truscelli, K.
    Giannini, R.
    Baldi, G. G.
    Altavilla, A.
    Ciarlo, A.
    Granetto, C.
    Fea, E.
    Fontanini, G.
    Basolo, F.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20
  • [23] A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial
    Johnsson, A.
    Hagman, H.
    Frodin, J. -E.
    Berglund, A.
    Keldsen, N.
    Fernebro, E.
    Sundberg, J.
    Christensen, R. De Pont
    Spindler, K-L. Garm
    Bergstrom, D.
    Jakobsen, A.
    ANNALS OF ONCOLOGY, 2013, 24 (09) : 2335 - 2341
  • [24] Randomized phase II trial of capecitabine (X) versus X plus erlotinib (E) in patients (pts) with metastatic colorectal cancer (mCRC): Differential impact of KRAS.
    Vincent, M. D.
    Welch, S.
    Soulieres, D.
    Sanatani, M. S.
    Whiston, F.
    Stitt, L.
    O'Connell, A.
    MacKenzie, M. J.
    Kocha, W. I.
    Kerr, I. G.
    Dingle, B. H.
    Malpage, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Retrospective review of FOLFIRI with or without bevacizumab (bev) for patients (pts) with metastatic colorectal cancer (mCRC): Reviewing a single-center standard clinical practice
    Maroun, Jean Alfred
    Marginean, Horia
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [26] Impact of bevacizumab (bev) on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCRC): A population-based study
    Renouf, D. J.
    Lim, H. J.
    Speers, C.
    Villa, D.
    Gill, S.
    Blanke, C. D.
    O'Reilly, S. E.
    Kennecke, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] Impact of colorectal liver metastases (CRLM) in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in the phase 3 SUNLIGHT trial
    Tabernero, Josep
    Prager, Gerald W.
    Taieb, Julien
    Calleja, Elizabeth Martine
    Liu, Mei
    Amellal, Nadia
    Fakih, Marwan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
    Van Cutsem, Eric
    Vervenne, Walter L.
    Bennouna, Jaafar
    Humblet, Yves
    Gill, Sharlene
    Van Laethem, Jean-Luc
    Verslype, Chris
    Scheithauer, Werner
    Cosaert, Aijing Shang Jan
    Moore, Malcolm J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) : 2231 - 2237
  • [29] A phase Ib study of the safety and efficacy of atezolizumab (atezo) plus bevacizumab (bev) plus cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J.
    Lieu, C.
    Raghav, K. P. S.
    Argiles, G.
    Cubillo, A.
    Qu, X.
    Yan, Y.
    Merchant, M.
    Zeuner, H.
    Gallo, J. D.
    Segal, N. H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [30] Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD])
    Tabernero, J.
    Aranda, E.
    Gomez, A.
    Massuti, B.
    Sastre, J.
    Abad, A.
    Valladares, M.
    Rivera, F.
    Safont, M.
    Diaz-Rubio, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345